6533b7d8fe1ef96bd126adf6
RESEARCH PRODUCT
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models
Filippo SprianoS. O’brienMarilia BarrecaOlivier P. ThomasMaria Miguel-gordoFrancesco BertoniAlberto J. ArribasLaurence K. Jenningssubject
Marine spongesAntitumor activityCancer ResearchlymphomaBiologymedicine.diseaseLymphomaLead (geology)OncologymedicineCancer researchanti-tumor activityInvertebratemarine spongedescription
Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphomas, accounting for 30%-40% of new cases each year. Despite the big improvements achieved in the treatment, still 25–40% of patients still succumb due to refractory or relapsed disease. This highlights the need of new drugs for this cancer. The marine environment has recently been recognized as a source of anti-cancer compounds, as demonstrated by different marine drugs approved by different regulatory agencies (trabectedin, cytarabine, eribulin, plitidepsin) or as components of antibody drug conjugates for lymphoma patients (monomethyl auristatin E in polatuzumab vedotin and brentuximab vedotin). Here, we present a large screening of fractions obtained from different marine invertebrates collected in Ireland and in the Pacific Ocean on DLBCL cell lines
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-10-01 |